Effects of omega-3 fatty acids supplementation on oxidative stress and mmp2/9 in patients with gastric cancer during chemotherapy
A double blind clinical trial study was conducted on 30 adult patients with different kinds of gastric malignancies during chemotherapy in Ardebil, Iran in 2010. After measurement of anthropometric and biochemical factors, about 3 g omega-3 fatty acid and placebo were given daily to omega and placebo groups for 6 weeks, respectively. Blood samples were taken to measure lipid profiles, MMP2, MMP9 and MDA, total antioxidants, PON1 and arylesterase enzymes at the beginning and at the end of 4th and 6th weeks. After interventions; weight, HDL, PON1 and arylesterase enzymes in omega group were significantly higher than placebo group at the end of 6th week (p<0.05). The serum levels of MMP2, MMP9 and MDA in omega group were less than placebo group (p<0.05). While weight, BMI, HDL, total antioxidants, arylesterase serum and PON1 were significantly increased, MMP2 and MMP9 were decreased after consumption of omega-3 fatty acid (p<0.05). In placebo group, the mean of weight and HMI were decreased but MDA, MMP2 and MMP9 were increased significantly during study (p<0.05). This study showed that the omega-3 fatty acid may be useful as a good complementary therapy for gastric cancer patients during chemotherapy.